Global Rheumatoid Arthritis Drugs Market Aims for $49.86 Billion by 2030: Addressing a Growing Autoimmune Challenge - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

The global Rheumatoid Arthritis Drugs Market is on track to achieve a significant milestone, projected to reach a value of US$ 49.86 billion by 2030.

Rheumatoid Arthritis (RA) is an autoimmune disorder characterized by inflammation and joint pain. It occurs when the immune system misfires and attacks the synovium, the lining of the joints. RA commonly affects symmetrical joints on both sides of the body, such as hands and knees.

Additionally, RA can impact other bodily systems like the lungs, heart, eyes, and circulatory system. About 40% of people with rheumatoid arthritis experience symptoms in multiple areas of the body, including nerve tissue, eyes, lungs, salivary glands, and skin. Symptoms' severity varies, and in some cases, they may be absent altogether. The condition is more prevalent among females, with 2.5 females affected for every male. Rheumatoid Arthritis can manifest as early as age 16 and persist until age 40.

In a healthy individual, the immune system combats foreign invaders like bacteria and viruses. An autoimmune disease like RA arises when the immune system mistakes the body's cells as invaders and releases inflammatory substances that attack those cells. In RA, the synovium, the tissue lining a joint that produces fluid for smooth joint movement, becomes the target. The affected joint area can become swollen, tender, and uncomfortable due to the thickened inflammatory synovium, making joint movement difficult.

In May 2023, Eli Lilly and Company reported positive results from a phase 2a study on peresolimab in rheumatoid arthritis (RA). Peresolimab exhibited effectiveness with comparable adverse event rates to the placebo group, meeting the primary goal of the study. These findings provide preliminary clinical evidence for the potential of activating the endogenous PD-1 inhibitory pathway in the treatment of rheumatologic disorders. The study evaluated the safety and efficacy of peresolimab in adults with moderate-to-severe RA who had not responded well to previous conventional, biologic, or synthetic disease-modifying antirheumatic medications (DMARDs).

Projected Growth and Market Dynamics

The Rheumatoid Arthritis Drugs Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.72% from 2022 to 2030. A study published in Rheumatology International titled "The global prevalence of rheumatoid arthritis (RA): a meta-analysis based on a systematic review" estimated the global prevalence of RA to be 0.46 percent. The market is expected to expand due to increased adoption of RA therapies.

Key drivers of the global Rheumatoid Arthritis Drugs Market include the availability of high-cost medications, efficient reimbursement methods, rising prevalence rates, and regulatory standards. As the prevalence of RA increases and awareness about condition-specific treatments grows, the market is poised for growth. Additionally, factors such as aging populations, the emergence of biosimilars and biologics, and robust regulatory policies are expected to contribute to revenue growth. The market for treating rheumatoid arthritis was valued at US$ 34.47 billion in 2022.

Treatment Landscape and Trends

The market for treating rheumatoid arthritis is dominated by injectable therapies due to their faster and more effective action compared to oral treatments. Injectable therapies, particularly advanced biologics, are necessary due to the complexity of the disease, often requiring targeted administration through injections. These therapies are preferred by medical professionals for their ability to target the underlying immune pathways of the disease, providing tailored treatment.

Biopharmaceuticals Lead the Way

In the realm of therapeutic molecules, biopharmaceuticals are leading the treatment industry for rheumatoid arthritis. These cutting-edge drugs, including TNF inhibitors and interleukin inhibitors, revolutionize treatment by reducing inflammation, preventing joint degeneration, and significantly improving pain relief, joint function, and quality of life. As our understanding of rheumatoid arthritis processes deepens, novel and targeted biopharmaceutical therapies are being developed, solidifying their position as the top treatment modality on the market.

Online Distribution Channels and Future Trends

The distribution landscape is shifting towards substantial growth in online distribution channels for rheumatoid arthritis drugs. Patients can now conveniently order medications from home through the expansion of e-commerce and digital platforms, enhancing accessibility and convenience. With telemedicine becoming more prevalent, virtual consultations and electronic prescriptions make online medication purchase easier. Patients benefit from a wide range of products, competitive prices, and access to information and support services. These factors are contributing to the rapid growth of online distribution channels in the market for treating rheumatoid arthritis.

Regional Outlook

North America is expected to continue holding a substantial market share in the treatment of rheumatoid arthritis. In the United States, for example, approximately 1 in 4 adults (23.7%) have arthritis, as per the Centers for Disease Control and Prevention (CDC). The high prevalence of rheumatoid arthritis in the US, along with robust market players and innovative pharmaceutical research, drives market expansion.

Leading Companies Mentioned:

• Eli Lilly and Co.
• Fibrogen Inc.
• Biogen Inc.
• Merck & Co. Inc.
• Abbvie Inc.
• Roche Holding AG
• Novartis AG
• Johnson & Johnson

Key Attributes:

Key Topics Covered:

1. Introduction

2. Research& Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Rheumatoid Arthritis Drug Market

6. Rheumatoid Arthritis Drug Market - Share Analysis

7. Product Type - Rheumatoid Arthritis Drug Market

8. Therapeutic Molecules - Rheumatoid Arthritis Drug Market

9. Surgery - Rheumatoid Arthritis Drug Market

10. Sales Channel - Rheumatoid Arthritis Drug Market

11. Distribution Channel - Rheumatoid Arthritis Drug Market

12. Country - Rheumatoid Arthritis Drug Market

13. Rheumatoid Arthritis Drug Market - Porter's Five Forces Analysis

14. Rheumatoid Arthritis Drug Market - SWOT Analysis

15. Key Players

For more information about this report visit https://www.researchandmarkets.com/r/bs7gv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900